CELLINK was granted € 2.5M from the SME Instrument, HORIZON 2020, phase 2.
The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. The company has, within 12 months, been able to commercialize products in more than 40 countries and sold to more than hundreds of prestigious labs around the world, such as Harvard, MIT, Princeton, and FDA.
CELLINK has been awarded project funding from the EU for the project “SilkFUSION – Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research.
GAEU helped structuring the project, limiting the scope and building business argumentation. GAEU made a very big difference in the process by preparing the client for the pitch deck in Brussels, creating the presentation needed and providing the client with coaching before the interview in Brussels.
“Collaborating with GAEU has been great! The team is very responsive, knowledgable, and supportive. Their work and efforts will help us ensure long term success. A company to depend on.”
Dr. Erik Gatenholm, CEO, CELLINK